Gillespie S H
Royal Free and University College Medical School, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK.
Int J Antimicrob Agents. 2001 Mar;17(3):171-6. doi: 10.1016/s0924-8579(00)00340-x.
Antibiotic resistance poses a serious threat to modern medical practice making treatment more difficult and is associated with increased mortality among patients infected with resistant organisms. There is clear evidence that acquisition of resistance is associated with a decrease in the fitness of the organisms at least in the short term. Evidence from in vitro experiments indicates that bacteria have the ability to adapt to this deficit and recover fitness on serial passage. More recent results show that identical organisms isolated from patients in outbreaks have an initial deficit but that adaptation occurs in vivo. Strategies directed towards controlling resistance must move beyond wishful thinking that supposes that these organisms will disappear merely with control of prescribing. In some cases, resistance will not disappear because there is no evolutionary disadvantage in being resistant once adaptation has taken place. It is important, therefore, that we direct our efforts towards preventing primary resistance emerging and in limiting the spread of resistant strains. Ultimately, we must look again to new drug discovery to improve our therapeutic armoury.
抗生素耐药性对现代医学实践构成了严重威胁,使治疗更加困难,并与感染耐药菌的患者死亡率增加有关。有明确证据表明,获得耐药性至少在短期内与细菌适应性下降有关。体外实验证据表明,细菌有能力适应这种缺陷,并在连续传代过程中恢复适应性。最近的结果表明,在疫情中从患者身上分离出的相同细菌最初存在缺陷,但适应性会在体内发生。旨在控制耐药性的策略必须超越一厢情愿的想法,即认为这些细菌仅仅通过控制处方就会消失。在某些情况下,耐药性不会消失,因为一旦发生适应性变化,耐药就没有进化劣势。因此,重要的是我们应致力于预防原发性耐药的出现,并限制耐药菌株的传播。最终,我们必须再次着眼于新药研发,以改善我们的治疗手段。